FTI Consulting's Fourth Annual Life Sciences Investor Survey Highlights Continued Optimism for Sector

   FTI Consulting's Fourth Annual Life Sciences Investor Survey Highlights
                        Continued Optimism for Sector

Investor Study Forecasts Positive Performance in Healthcare and Life Sciences
Stocks, and Strength in Industry IPO and M&A Market in 2014

PR Newswire

WEST PALM BEACH, Fla., Feb. 27, 2014

WEST PALM BEACH, Fla., Feb. 27, 2014 /PRNewswire/ -- FTI Consulting, Inc.
(NYSE: FCN), the global business advisory firm dedicated to helping
organizations protect and enhance their enterprise value, today announced the
results of the firm's fourth annual Life Sciences Investor Survey of European
and U.S. institutional investors on a number of key industry-related topics.
Conducted by the firm's Strategic Communications segment, the study's findings
underscore investors' overall optimism toward the outlook for healthcare stock
performance and the anticipated continued strength of the transaction
environment in the sector. The research also revealed a number of key trends
in shareholder engagement for healthcare and life sciences companies to

The study found 67 percent of investors expect healthcare to outperform or
generate equal returns to the broader market in 2014. Seventy-seven percent of
investors believe current healthcare valuations are being supported by a
foundation of fresh innovation, science, restructuring and a favorable growth
outlook — and do not reflect a sector investment bubble.

According to FTI Consulting's research, the industry's transaction environment
is expected to remain relatively robust in 2014. After a total of 43 venture
capital-backed U.S. healthcare initial public offerings (IPOs) raised $2.7
billion in 2013, compared to only 14 U.S. healthcare IPOs in 2012 that raised
$714 million, an overwhelming 84 percent of investors surveyed expect the IPO
window to remain open for life sciences companies for at least six more

Moreover, 65 percent of investors believe this healthy appetite for healthcare
IPOs is fueling a more expensive deal and merger and acquisition (M&A)
environment. This was certainly the case in 2013, when 60 transactions with a
combined value of $77 billion were completed compared to 2012 when 51
transactions with a combined value of $44 billion were completed. The average
size of each transaction in 2013 was 49 percent higher than in the prior year.

"With 59 percent of investors anticipating a significant or moderate increase
in M&A among healthcare and life sciences companies, 2014 could be another
record year for the sector in terms of both the number and value of deals,"
said Elizabeth Saunders, Senior Managing Director and Americas Chairman in the
Strategic Communications segment at FTI Consulting.

"The IPO and M&A-related data derived from this study indicate strong
optionality potential for development-stage companies," said Barbara Ryan,
Managing Director in the Strategic Communications segment's Healthcare & Life
Sciences industry team at FTI Consulting. "To maximize this optionality, these
companies must build a corporate narrative that clearly defines the investment
case, and then communicate that investment case 'early and often' via
presentations at healthcare investment conferences and one-on-one meetings
with institutional investors."

The FTI Consulting research also found the majority of investors view direct
interaction with companies as their most preferred information source — with
industry conferences, investor day events, non-deal roadshows and investment
conferences identified as the most important communication activities. Of
significance, the study showed a meaningful geographical split in the number
of investor interactions preferred prior to an investment decision. U.S.
investors prefer three to four direct interactions with a management team
prior to making an investment decision, while European investors generally
arrive at an investment decision following one to two interactions.

FTI Consulting will be hosting a webinar on Thursday, March 13, 2014 at 10
a.m. EDT where finance and industry experts will discuss the findings from the
firm's Life Sciences Investor Survey in greater detail, and explore the market
dynamics currently driving investment decisions in the industry.

Featured speakers will include:

  oJudy Brown, Executive Vice President and Chief Financial Officer, Perrigo
  oTom Crawford, Senior Managing Director, FTI Consulting, Strategic
  oAlan Hartman, Partner, Centerview Partners
  oBarbara Ryan, Managing Director, FTI Consulting, Strategic Communications

This webinar is complimentary, aimed at corporate advisers and executives in
the healthcare and life sciences sector. To register for the webinar and
receive the full report, please visit:

Research Methodology

The Strategic Communications segment of FTI Consulting executed primary
research among 83 healthcare-focused, buy-side investors from Europe and the
U.S. in December 2013, so as to provide a diverse and global perspective on
the current state of the healthcare industry.

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping
organizations protect and enhance enterprise value in an increasingly complex
legal, regulatory and economic environment. With more than 4,200 employees
located in 26 countries, FTI Consulting professionals work closely with
clients to anticipate, illuminate and overcome complex business challenges in
areas such as investigations, litigation, mergers and acquisitions, regulatory
issues, reputation management, strategic communications and restructuring. The
Company generated $1.65 billion in revenues during fiscal year 2013. More
information can be found at www.fticonsulting.com.

Investor Contact:
Mollie Hawkes

Media Contact:
Matthew Clark

SOURCE FTI Consulting, Inc.

Website: http://www.fticonsulting.com
Press spacebar to pause and continue. Press esc to stop.